Ondansetron Treatment in Tourette's Disorder: A 3-Week, Randomized, Double-Blind, Placebo-Controlled Study
J Clin Psychiatry 2005;66(4):499-503
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: The aim of the present study was to
evaluate the efficacy of ondansetron, a selective 5-HT3 antagonist, in the treatment of Tourette's disorder.
Method: Participants (N = 30) aged 12 to 46 years,
diagnosed with DSM-IV Tourette's disorder and resistant to
previous haloperidol treatment, were enrolled in a 3-week,
randomized, double-blind, placebo-controlled outpatient study.
Assessments were conducted at baseline and once a week during the
study period. Scales used included the Tourette's Syndrome Global
Scale (TSGS), the Yale Global Tic Severity Scale (YGTSS), and the
Yale-Brown Obsessive Compulsive Scale. Ondansetron dose was 8,
16, and 24 mg/day in the first, second, and third weeks,
Results: A significant positive effect of
ondansetron on tic severity, as assessed by the TSGS, was noted
(baseline vs. endpoint: mean ± SD = 29.62 ± 20.33 vs. 20.58 ± 12.82,
p = .002 vs. placebo). However, no significant effect was detected
upon assessing ondansetron/placebo effect on tic severity with
the YGTSS (baseline vs. endpoint: mean ± SD = 24.04 ± 9.44 vs.
17.50 ± 9.48, p = .15 vs. placebo). No change in
obsessive-compulsive symptoms was noted in either group. Adverse
effects included mild and transient abdominal pain.
Conclusions: Ondansetron may have anti-tic
effects in patients with Tourette's disorder. Large-scale,
double-blind studies should further assess the anti-tic efficacy